Moving Forward in Alzheimer’s Disease
New Management Paradigms for Patients and Healthcare Systems
Answers to Commonly Asked Questions in Alzheimer’s Disease
The future of anti-amyloid trials.
Aisen PS, Cummings J, Doody R, et al. J Prev Alzheimers Dis. 2020;7(3):146-151.
2021 Alzheimer’s disease facts and figures.
Alzheimer’s Association.
Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.
Babulal GM, Quiroz YT, Albensi BC, et al. Alzheimers Dement. 2019;15(2):292-312.
Neuropathological stageing of Alzheimer-related changes.
Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.
EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease.
Budd Haeberlein S, von Hehn C, Tian Y, et al. Presented at: 12th Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
Chételat G, Arbizu J, Barthel H, et al. Lancet Neurol. 2020;19(11):951-962.
Biomarkers for Alzheimer's disease. Where we stand and where we are headed.
Chrem Méndez P, Surace E, Bérgamo Y, et al. Medicina (B Aires). 2019;79(Spec 6/1):546-551.
Imaging and molecular mechanisms of Alzheimer's disease: a review.
Femminella GD, Thayanandan T, Calsolaro V, et al. Int J Mol Sci. 2018;19(12):3702.
Costly new Alzheimer disease medications on the horizon—financing alternatives for Medicare.
Fleming WK, Brown CR, Shrank WH. JAMA Health Forum. 2020;1(9):e201148.
Dose- and time- dependent changes in plasma p-tau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials
Hanson O, Nisenbaum L, Chen T, et al. Presented at: 14th Clinical Trials on Alzheimer’s Disease; November 9-12, 2021; virtual conference.
Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty.
Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Front Pharmacol. 2020;11:261.
Donanemab in early Alzheimer's disease.
Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021;384(18):1691-1704.
High performance plasma amyloid-β biomarkers for Alzheimer's disease.
Nakamura A, Kaneko N, Villemagne VL, et al. Nature. 2018;554(7691):249-254.
Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.
Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.
Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.
Salloway S, Chalkias S, Barkhof F, et al. JAMA Neurol. 2022;79(1):13-21.
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Res Ther. 2021;13(1):80.
Potential new approaches for diagnosis of Alzheimer’s disease and related dementias.
Turner RS, Stubbs T, Davies DA, Albensi BC. Front Neurol. 2020;11:496.
What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?
Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):1-4.
Economic burden of Alzheimer disease and managed care considerations.
Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.
Clinical Practice Guidelines
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Albert MS, DeKosky ST, Dickson D, et al. Alzheimers Dement. 2011;7(3):270-279.
The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.
McKhann GM, Knopman DS, Chertkow H, et al. Alzheimers Dement. 2011;7(3):263-269.
Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Petersen RC, Lopez O, Armstrong MJ, et al. Neurology. 2018;90(3):126-135.
Patient and Caregiver Resources
AD8 dementia screening interview
Alzheimer’s Association
Alzheimer’s Questionnaire
General Practitioner Assessment of Cognition (GPCOG)
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
Mini-Mental State Exam (MMSE) Alzheimer’s / dementia test: administration, accuracy and scoring
Memory Impairment Screen (MIS)
Montreal Cognitive Assessment Test (MoCA) for dementia & Alzheimer’s
Standardized Mini-Cog© Instrument
Pathophysiology of Alzheimer's Disease
Module 1
| Faculty: | Sharon Cohen, MD; R. Scott Turner, MD, PhD |
| Release: | 02/17/2022 |
| Expiration: | 02/17/2023 |
Evaluation and Diagnosis of MCI and AD
Module 2
| Faculty: | Sharon Cohen, MD; R. Scott Turner, MD, PhD |
| Release: | 02/17/2022 |
| Expiration: | 02/17/2023 |
Management of AD
Module 3
| Faculty: | Sharon Cohen, MD; R. Scott Turner, MD, PhD |
| Release: | 02/17/2022 |
| Expiration: | 02/17/2023 |
Barriers to Optimizing Alzheimer's Disease Management
Module 4
| Faculty: | Sharon Cohen, MD; R. Scott Turner, MD, PhD |
| Release: | 02/17/2022 |
| Expiration: | 02/17/2023 |
